Related Experiment Video
Updated: Jul 16, 2025
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma
Mohamed A Gouda1, Maria A Zarzour2, Ara A Vaporciyan3
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.
Insights
Pazopanib demonstrated exceptional tumor control in a patient with a rare EWSR1-NFATC2 fusion-positive bone sarcoma for over five years. This case highlights pazopanib
Area of Science:
- Oncology
- Molecular Biology
- Surgical Oncology
Background:
- Pazopanib is an approved multi-kinase inhibitor for advanced renal cell carcinoma and soft tissue sarcoma.
- Bone sarcomas, particularly rare fusion-positive types, present therapeutic challenges.
Observation:
- A patient with an EWSR1-NFATC2 fusion-positive bone sarcoma received pazopanib and surgery.
- Exceptional tumor control was observed for over five years.
Findings:
- Pazopanib, in combination with surgery, achieved durable tumor control in a patient with EWSR1-NFATC2-positive bone sarcoma.
- Literature review on EWSR1-NFATC2 sarcomas and pazopanib efficacy in bone sarcomas was conducted.
Implications:
- This case suggests pazopanib may be a viable treatment option for specific bone sarcoma subtypes.
- Further research into targeted therapies for EWSR1-NFATC2 sarcomas is warranted.
